JANEL CORP
No SEC Form 4 filings for $JANL in the last 30 days.
See all $JANL insider activity →Janel Corp. acquired EnCor Biotechnology for $17M, funded by $11.96M in cash and a $5.04M note. Janel amended its credit agreement, adding $15M in acquisition facility commitments to support the deal. The acquisition aims to expand Janel's antibodies and reagents business.
JANEL CORP (JANL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement Purchase Agreement On October 20, 2026, Janel Corporation, a Nevada corporation (the “Company”), through its wholly owned subsidiary Antibodies Incorporated, a California corporation (“Antibodies Inc.”), entered into a Purchase
GRAVES GREGORY B purchased 395 shares of JANEL CORP (JANL) at an average of $49.52 ($48.00–$50.00) across 2 trades over 2026-09-11 to 2026-09-14.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning JANL (JANEL CORP). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent JANL coverage spans insider activity, mergers & acquisitions and regulation.
The acquisition expands Janel's antibodies and reagents business, likely modestly boosting its growth outlook.
The deal expands Janel's biotech portfolio and adds debt, likely creating modest upside pressure as investors price the strategic acquisition.
Small insider purchase signals confidence but limited market impact.
Small insider purchase by a director; unlikely to move the stock.
TKO Group Holdings said in an SEC filing that Janel Grant’s lawsuit against Vince McMahon and WWE moved from federal court to private arbitration. TKO said Grant agreed to arbitrate on July 20 and dismissed her federal case four days later, ending the public proceedings. Other items covered WWE and AEW storylines and injuries.
AlphAI scores every news story that mentions JANL with an AI model for sentiment and relevance, and aggregates insider trades from JANEL CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Janel Corp. acquired EnCor Biotechnology for $17M, funded by $11.96M in cash and a $5.04M note. Janel amended its credit agreement, adding $15M in acquisition facility commitments to support the deal. The acquisition aims to expand Janel's antibodies and reagents business.
1 min readJANEL CORP (JANL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement Purchase Agreement On October 20, 2026, Janel Corporation, a Nevada corporation (the “Company”), through its wholly owned subsidiary Antibodies Incorporated, a California corporation (“Antibodies Inc.”), entered into a Purchase
2 min readGRAVES GREGORY B purchased 395 shares of JANEL CORP (JANL) at an average of $49.52 ($48.00–$50.00) across 2 trades over 2026-09-11 to 2026-09-14.
1 min readGRAVES GREGORY B purchased 400 shares of JANEL CORP (JANL) at $50.00 on 2026-09-09.
1 min readTKO Group Holdings said in an SEC filing that Janel Grant’s lawsuit against Vince McMahon and WWE moved from federal court to private arbitration. TKO said Grant agreed to arbitrate on July 20 and dismissed her federal case four days later, ending the public proceedings. Other items covered WWE and AEW storylines and injuries.
2 min readTKO’s latest Form 10-Q cites an arbitration agreement tied to Janel Grant’s claims against WWE and Vince McMahon. TKO describes Grant as a former WWE employee and summarizes her Jan 25, 2024 lawsuit, Laurinaitis’ May 30, 2025 dismissal, and a July 20, 2026 arbitration agreement followed by a July 24, 2026 voluntary dismissal with prejudice. No arbitration updates were provided.
3 min readGRAVES GREGORY B purchased 225 shares of JANEL CORP (JANL) at $42.00 on 2026-06-02.
2 min readGRAVES GREGORY B purchased 900 shares of JANEL CORP (JANL) at an average of $44.11 ($43.00–$45.00) across 2 trades on 2026-05-28.
2 min read
